MX2010010245A - Inhibidores de ns5b de virus de la hepatitis c de indolobenzadiazepina fusionados a dioxolano y dioxolanona. - Google Patents

Inhibidores de ns5b de virus de la hepatitis c de indolobenzadiazepina fusionados a dioxolano y dioxolanona.

Info

Publication number
MX2010010245A
MX2010010245A MX2010010245A MX2010010245A MX2010010245A MX 2010010245 A MX2010010245 A MX 2010010245A MX 2010010245 A MX2010010245 A MX 2010010245A MX 2010010245 A MX2010010245 A MX 2010010245A MX 2010010245 A MX2010010245 A MX 2010010245A
Authority
MX
Mexico
Prior art keywords
indolobenzadiazepine
dioxolanone
dioxolane
fused
hcv ns5b
Prior art date
Application number
MX2010010245A
Other languages
English (en)
Inventor
John F Kadow
John A Bender
Zhong Yang
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of MX2010010245A publication Critical patent/MX2010010245A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Abstract

La invención proporciona compuestos de la fórmula I, incluyendo sus sales, así como composiciones y métodos para usar los compuestos. Los compuestos tienen actividad contra virus de la hepatitis C (HCV) y son útiles para tratar a aquellos infectados con HCV.
MX2010010245A 2008-03-27 2009-03-26 Inhibidores de ns5b de virus de la hepatitis c de indolobenzadiazepina fusionados a dioxolano y dioxolanona. MX2010010245A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3996708P 2008-03-27 2008-03-27
PCT/US2009/038441 WO2009120890A1 (en) 2008-03-27 2009-03-26 Dioxolane and dioxolanone fused indolobenzadiazepine hcv ns5b inhibitors

Publications (1)

Publication Number Publication Date
MX2010010245A true MX2010010245A (es) 2010-10-05

Family

ID=40790426

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010010245A MX2010010245A (es) 2008-03-27 2009-03-26 Inhibidores de ns5b de virus de la hepatitis c de indolobenzadiazepina fusionados a dioxolano y dioxolanona.

Country Status (7)

Country Link
US (1) US8138171B2 (es)
EP (1) EP2268643B1 (es)
JP (1) JP2011515496A (es)
KR (1) KR20100134699A (es)
CN (1) CN101981038B (es)
MX (1) MX2010010245A (es)
WO (1) WO2009120890A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2374870T3 (es) 2008-03-27 2012-02-22 Bristol-Myers Squibb Company Inhibidores de ns5b de vhc de indolobenzadiazepina fusionada con heterocíclicos aromáticos.

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7528102B2 (en) * 2002-08-09 2009-05-05 Henkel Kgaa Fragrance release system
PT1719773E (pt) 2004-02-24 2009-06-03 Japan Tobacco Inc Compostos heterotetracíclicos fundidos e a sua utilização como inibidores da polimerase do hcv
US7153848B2 (en) 2004-08-09 2006-12-26 Bristol-Myers Squibb Company Inhibitors of HCV replication
US7348425B2 (en) 2004-08-09 2008-03-25 Bristol-Myers Squibb Company Inhibitors of HCV replication
CA2585113A1 (en) 2004-10-26 2006-05-04 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Tetracyclic indole derivatives as antiviral agents
GB0423767D0 (en) * 2004-10-26 2004-12-01 Angeletti P Ist Richerche Bio Therapeutic compounds
GB0518390D0 (en) 2005-09-09 2005-10-19 Angeletti P Ist Richerche Bio Therapeutic compounds
US7399758B2 (en) 2005-09-12 2008-07-15 Meanwell Nicholas A Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7473688B2 (en) 2005-09-13 2009-01-06 Bristol-Myers Squibb Company Indolobenzazepine HCV NS5B inhibitors
US7456165B2 (en) 2006-02-08 2008-11-25 Bristol-Myers Squibb Company HCV NS5B inhibitors
GB0608928D0 (en) * 2006-05-08 2006-06-14 Angeletti P Ist Richerche Bio Therapeutic agents
US7456166B2 (en) 2006-05-17 2008-11-25 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7521443B2 (en) 2006-05-17 2009-04-21 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7521441B2 (en) 2006-05-22 2009-04-21 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
ES2343914T3 (es) 2006-05-25 2010-08-12 Bristol-Myers Squibb Company Inhibidores de ns5b de hcv de indolobenzazepina condensada con ciclopropilo.
WO2007140200A2 (en) 2006-05-25 2007-12-06 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors
US7452876B2 (en) 2006-06-08 2008-11-18 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7541351B2 (en) 2007-01-11 2009-06-02 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7517872B2 (en) 2007-02-22 2009-04-14 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7998951B2 (en) 2007-03-05 2011-08-16 Bristol-Myers Squibb Company HCV NS5B inhibitors
US7547690B2 (en) 2007-03-14 2009-06-16 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
US7538102B2 (en) 2007-03-14 2009-05-26 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
US7541353B2 (en) 2007-03-14 2009-06-02 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7521444B2 (en) 2007-03-14 2009-04-21 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7538103B2 (en) 2007-03-15 2009-05-26 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US20090018163A1 (en) 2007-07-11 2009-01-15 Bristol-Myers Squibb Company Substituted Heterocyclic Ethers and Their Use in CNS Disorders
US8124601B2 (en) 2007-11-21 2012-02-28 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
US8129367B2 (en) 2007-11-21 2012-03-06 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
MX2010010061A (es) 2008-03-27 2010-09-30 Bristol Myers Squibb Co Compuestos para el tratamiento de hepatitis c.
US8143244B2 (en) 2009-02-26 2012-03-27 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors

Also Published As

Publication number Publication date
EP2268643B1 (en) 2014-08-06
US20110020277A1 (en) 2011-01-27
US8138171B2 (en) 2012-03-20
EP2268643A1 (en) 2011-01-05
AU2009228214A1 (en) 2009-10-01
KR20100134699A (ko) 2010-12-23
WO2009120890A1 (en) 2009-10-01
JP2011515496A (ja) 2011-05-19
CN101981038A (zh) 2011-02-23
CN101981038B (zh) 2013-07-10

Similar Documents

Publication Publication Date Title
TW200745120A (en) Indolobenzazepine HCV NS5B inhibitors
WO2010030538A3 (en) Compounds for the treatment of hepatitis c
SI1987038T1 (sl) Hcv ns5b inhibitorji
ATE469155T1 (de) Cyclopropyl-fusionierte indolbenzazepin-hcv-ns5b- hemmer
SI2209789T1 (sl) Ciklopropil zliti indolobenzazepin hcv ns5b inhibitorji
MX2010008749A (es) Inhibidores del virus de la hepatitis c.
MX2010008699A (es) Derivados heterociclicos como inhibidores de virus de la hepatitis c.
EA201100390A1 (ru) Соединения для лечения гепатита с
MY152070A (en) Macrocyclic quinxaline compounds as hcv ns3 protease inhibitors
MX2010008531A (es) Derivados de bifenilo conformacionalmente restringido para uso como inhibidores del virus de la hepatitis c.
MX2012008443A (es) Nucleosidos antiviricos.
MX2009009473A (es) Compuestos para el tratamiento de hepatitis c.
TN2012000264A1 (en) Hepatitis c virus inhibitors
TN2012000214A1 (en) Hepatitis c virus inhibitors
CO6190510A2 (es) Inhibidores del virus de la hepatitis c
MY152971A (en) Hepatitis c virus inhibitors
MX2011008045A (es) Inhibidores del virus de la hepatitis c.
MX2009004888A (es) Inhibidores del virus de la hepatitis c.
MX2011009644A (es) Inhibidores del virus de la hepatitis c.
MX2012003170A (es) Compuestos heterociclicos antivirales.
MX2013002927A (es) Inhibidores del virus de la hepatitis c.
MX2013001237A (es) Compuestos inhibidores del virus de la hepatitis c.
ATE522532T1 (de) Verbindungen zur behandlung von hepatitis c
MX2010001416A (es) Compuesto para el tratamiento de la hepatitis c.
ATE494291T1 (de) Verbindungen zur behandlung von hepatitis c

Legal Events

Date Code Title Description
FG Grant or registration